Latest Headlines

31. epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. And Nippon Zenyaku Kogyo Co., Ltd. Enter Into License Agreement 11/17/2023

    epitoMAP Inc. (hereinafter "epitoMAP") and Animal Allergy Clinical Laboratories Inc. (hereinafter "AACL") entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. (hereinafter "ZENOAQ") on November 10, 2023.

32. Foundation Medicine Announces Collaboration With Pierre Fabre Laboratories To Develop Companion Diagnostics In Non-Small Cell Lung Cancer 11/15/2023

    Foundation Medicine, Inc., and Pierre Fabre Laboratories today announced a collaboration to develop Foundation Medicine’s high-quality genomic tests, FoundationOne®CDx and FoundationOne®Liquid CDx, as companion diagnostics for new targeted therapies to treat patients with non-small cell lung cancer (NSCLC).

33. FDA Grants Marketing Authorization Of First Test For Chlamydia And Gonorrhea With At-Home Sample Collection 11/15/2023

    Today, the U.S. Food and Drug Administration granted marketing authorization to LetsGetChecked for the Simple 2 Test. This is the first diagnostic test for chlamydia and gonorrhea with at-home sample collection to be granted marketing authorization.

34. Inflammatix Completes Technical Development For TriVerity™ Acute Infection And Sepsis Test System 11/15/2023

    Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the company has completed technical development for its TriVerity™ Acute Infection and Sepsis Test System, which includes the Myrna™ Instrument, and for the TriVerity™ Cartridge.

35. Geneoscopy Signs Multi-Year Agreement With Labcorp To Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test 11/14/2023

    Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced a strategic collaboration with Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services.

36. Biodesix Enhances Access To Nodify Lung Testing With Launch Of New Blood Draw Method 11/14/2023

    Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.

37. Oxford Nanopore And Day Zero Diagnostics Partner To Develop A New Class Of Bloodstream Infection Diagnostics 11/14/2023

    Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, and Day Zero Diagnostics (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, today announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.

38. Mayo Clinic Laboratories And Progentec® Collaborate To Bring Advanced Biomarker Testing Services To Patients With Autoimmune Diseases 11/14/2023

    Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec's suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market.

39. EU Approval Of AAV5 DetectCDx™ Provides Access To Companion Diagnostic For Hemophilia A Gene Therapy 11/10/2023

    ARUP Laboratories today announced that it has gained the Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR). AAV5 DetectCDx™ is a companion diagnostic developed in partnership with BioMarin Pharmaceutical Inc. to aid in the selection of adult patients eligible for BioMarin's new gene therapy for severe hemophilia A, valoctocogene roxaparvovec-rvox (ROCTAVIAN™).

40. H2U Secures Strategic Investment From Innotherapy As Recognition From Seoul Clinical Laboratories (SCL) 11/10/2023

    H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving recognition from South Korean medical laboratory powerhouse SCL (Seoul Clinical Laboratories). The partnership is solidified through a strategic investment from InnoTherapy Inc. (KOSDAQ: 246960), an affiliated company under the SCL Group.